The new playbook involves: Complex generics : Injectables, respiratory/nasal sprays, ophthalmic, transdermal products with technical barriers that limit competition Controlled substances : A sub-theme gaining momentum at Strides through its Chestnut Ridge facility and DEA quota Biosimilars : The next major wave is pembrolizumab, bevacizumab, ranibizumab, trastuzumab 505(b)(2) specialty: Branded differentiated products filed through the 505(b)(2) pathway (Alembics PIVYA) Peptides: Semaglutide filings by Zydus and Lupin as the frontier opportunity 17) Lupin US - $1.3 Billion and Still Accelerating FY26 US : ~$1.3 Bn (+~40% YoY) | Q4 US: 33,987 Mn ($371 Mn, +55% YoY) Lupins US performance is the headline story of Q4 FY26
Superior Absorption
To comply with Good Laboratory Practice regulations, the QC lab must have SOPs, test methods, specifications, registers, logs, and testing records in place
Ive worked with so many people with a history of binge eating disorder that might be a hundred pounds overweight, and its not just about them losing weight, looking good or being healthier, but those people have lost all psychological hope that it could ever change
The Long-Term Perspective: What Happens When You Stop GLP-1 Medication